Sugi Predict

Sugi Predict / Compounds / SCHEMBL4500958

SCHEMBL4500958

SCHEMBL4500958

O=Cc1n[nH]c2ccc(C(=O)O)cc12

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAP2K4 P45985 8/20 0.48
▸ MAPK1 P28482 5/20 0.48
▸ MAPK6 Q16659 5/20 0.48
▸ MAPKAPK3 Q16644 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ THRB P10828 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ ITK Q08881 1/20 0.43
▸ JAK2 O60674 1/20 0.43
▸ JAK1 P23458 1/20 0.43
▸ CHEK1 O14757 1/20 0.41
▸ KDR P35968 1/20 0.41
▸ SIRT2 Q8IXJ6 1/20 0.40
▸ SIRT1 Q96EB6 1/20 0.40
▸ HTR7 P34969 1/20 0.39
▸ MAPKAPK5 Q8IW41 1/20 0.39
▸ UNG P13051 1/20 0.39
▸ HCAR2 Q8TDS4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29957175 1.00 MAP2K4 (0.48) MAP2K4MAPK1MAPK6MAPKAPK3KDM4E
SCHEMBL29955795 0.87 KDR (0.53) MAP2K4MAPK1MAPK6MAPKAPK3ITK
SCHEMBL5249402 0.87 KDR (0.53) MAP2K4MAPK1MAPK6MAPKAPK3ITK
SCHEMBL29301505 0.86 SLC2A1 (0.43) MAP2K4MAPK1MAPK6MAPKAPK3ALDH1A1
SCHEMBL15060198 0.86 MAP2K4 (0.47) MAP2K4MAPK1MAPK6MAPKAPK3KDM4E
SCHEMBL17514121 0.83 MAP2K4 (0.48) MAP2K4MAPK1MAPK6MAPKAPK3KDM4E
SCHEMBL18812685 0.83 MAP2K4 (0.45) MAP2K4MAPK1MAPK6MAPKAPK3KDM4E
SCHEMBL18812686 0.83 MAP2K4 (0.45) MAP2K4MAPK1MAPK6MAPKAPK3KDM4E
SCHEMBL377682 0.82 KDM4E (0.48) MAP2K4KDM4EALDH1A1HPGD
SCHEMBL31172488 0.82 KDM4E (0.48) MAP2K4KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024210572-A1 NOVEL IMIDAZOLE DERIVATIVE AND USE THEREOF 주식회사 펠레메드 2024-10-10 — — WO disclosed
US-10858321-B2 Composition for inducing cell reprogramming GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-12-08 — — US disclosed
US-10858321-B2 Composition for inducing cell reprogramming GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-12-08 — — US disclosed
CN-106794172-B Composition for inducing cell reprogramming 光州科学技术院 2020-03-17 — — CN disclosed
US-20170158642-A1 COMPOSITION FOR INDUCING CELL REPROGRAMMING GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2017-06-08 — — US disclosed
US-20170158642-A1 COMPOSITION FOR INDUCING CELL REPROGRAMMING GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2017-06-08 — — US disclosed
US-20170158642-A1 COMPOSITION FOR INDUCING CELL REPROGRAMMING GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2017-06-08 — — US disclosed
EP-3165523-A2 COMPOSITION FOR INDUCING CELL REPROGRAMMING Gwangju Institute of Science and Technology (KR) 2017-05-10 — — EP disclosed
EP-3165523-A2 COMPOSITION FOR INDUCING CELL REPROGRAMMING Gwangju Institute of Science and Technology (KR) 2017-05-10 — — EP disclosed
US-20110034441-A1 INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF EPITHERIX, LLC (US) 2011-02-10 — — US disclosed
US-20090291968-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS GEORGES GUY 2009-11-26 — — US disclosed
CN-101400681-A Substituted indazole derivatives, their manufacture and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2009-04-01 — — CN disclosed
EP-2001882-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. Hoffmann-La Roche AG (CH) 2008-12-17 — — EP disclosed
WO-2007107346-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2007-09-27 — — WO disclosed
EP-1831224-A2 TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. Hoffmann-Roche AG (CH) 2007-09-12 — — EP disclosed
US-20060142247-A1 Tricyclic heterocycles HOFFMANN-LA ROCHE INC. 2006-06-29 — — US disclosed
WO-2006063841-A2 TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-06-22 — — WO disclosed
US-6884890-B2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2005-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291968-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS CYP3A43, CYP3A5, CYP3A7 MAP2K4 2425/4885MAPK1 3080/4885MAPK6 3504/4885
US-10858321-B2 Composition for inducing cell reprogramming MCL1, IRF3, STING1 MAP2K4 2990/4885MAPK1 2019/4885MAPK6 2379/4885
US-20110034441-A1 INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF WNT1, WNT3A, WNT3 MAP2K4 1109/4885MAPK1 367/4885MAPK6 898/4885
US-20060142247-A1 Tricyclic heterocycles CYP11B1, CYP11B2, CYP3A43 MAP2K4 3020/4885MAPK1 2747/4885MAPK6 3720/4885
US-20170158642-A1 COMPOSITION FOR INDUCING CELL REPROGRAMMING MCL1, IRF3, STING1 MAP2K4 2990/4885MAPK1 2019/4885MAPK6 2379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.